A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage
- PMID: 22343531
- PMCID: PMC3295328
- DOI: 10.1073/pnas.1113761109
A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage
Abstract
Inhibition of the ternary protein complex of the synaptic scaffolding protein postsynaptic density protein-95 (PSD-95), neuronal nitric oxide synthase (nNOS), and the N-methyl-D-aspartate (NMDA) receptor is a potential strategy for treating ischemic brain damage, but high-affinity inhibitors are lacking. Here we report the design and synthesis of a novel dimeric inhibitor, Tat-NPEG4(IETDV)(2) (Tat-N-dimer), which binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented high affinity of 4.6 nM, and displays extensive protease-resistance as evaluated in vitro by stability-measurements in human blood plasma. X-ray crystallography, NMR, and small-angle X-ray scattering (SAXS) deduced a true bivalent interaction between dimeric inhibitor and PDZ1-2, and also provided a dynamic model of the conformational changes of PDZ1-2 induced by the dimeric inhibitor. A single intravenous injection of Tat-N-dimer (3 nmol/g) to mice subjected to focal cerebral ischemia reduces infarct volume with 40% and restores motor functions. Thus, Tat-N-dimer is a highly efficacious neuroprotective agent with therapeutic potential in stroke.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Comment in
-
Stroke: Can PSD95 inhibitors widen the therapeutic window?Nat Rev Drug Discov. 2012 Mar 30;11(4):272. doi: 10.1038/nrd3716. Nat Rev Drug Discov. 2012. PMID: 22460120 No abstract available.
Similar articles
-
Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95.Nat Med. 2010 Dec;16(12):1439-43. doi: 10.1038/nm.2245. Epub 2010 Nov 21. Nat Med. 2010. PMID: 21102461
-
PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors.J Neurosci. 2007 Sep 12;27(37):9901-15. doi: 10.1523/JNEUROSCI.1464-07.2007. J Neurosci. 2007. PMID: 17855605 Free PMC article.
-
PSD-95 uncoupling from NMDA receptors by Tat- N-dimer ameliorates neuronal depolarization in cortical spreading depression.J Cereb Blood Flow Metab. 2017 May;37(5):1820-1828. doi: 10.1177/0271678X16645595. Epub 2016 Jan 1. J Cereb Blood Flow Metab. 2017. PMID: 27107027 Free PMC article.
-
Targeting protein-protein interactions with trimeric ligands: high affinity inhibitors of the MAGUK protein family.PLoS One. 2015 Feb 6;10(2):e0117668. doi: 10.1371/journal.pone.0117668. eCollection 2015. PLoS One. 2015. PMID: 25658767 Free PMC article.
-
PSD-95: An Effective Target for Stroke Therapy Using Neuroprotective Peptides.Int J Mol Sci. 2021 Nov 22;22(22):12585. doi: 10.3390/ijms222212585. Int J Mol Sci. 2021. PMID: 34830481 Free PMC article. Review.
Cited by
-
Site-specific phosphorylation of PSD-95 dynamically regulates the postsynaptic density as observed by phase separation.iScience. 2021 Oct 14;24(11):103268. doi: 10.1016/j.isci.2021.103268. eCollection 2021 Nov 19. iScience. 2021. PMID: 34761188 Free PMC article.
-
Accidental interaction between PDZ domains and diclofenac revealed by NMR-assisted virtual screening.Molecules. 2013 Aug 9;18(8):9567-81. doi: 10.3390/molecules18089567. Molecules. 2013. PMID: 23966078 Free PMC article.
-
GluN2B-containing NMDARs in the mammalian brain: pharmacology, physiology, and pathology.Front Mol Neurosci. 2023 May 31;16:1190324. doi: 10.3389/fnmol.2023.1190324. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37324591 Free PMC article. Review.
-
Reconstitution of multivalent PDZ domain binding to the scaffold protein PSD-95 reveals ternary-complex specificity of combinatorial inhibition.Structure. 2014 Oct 7;22(10):1458-66. doi: 10.1016/j.str.2014.08.006. Epub 2014 Sep 11. Structure. 2014. PMID: 25220472 Free PMC article.
-
The case for neuregulin-1 as a clinical treatment for stroke.Front Cell Neurosci. 2024 Apr 4;18:1325630. doi: 10.3389/fncel.2024.1325630. eCollection 2024. Front Cell Neurosci. 2024. PMID: 38638304 Free PMC article. Review.
References
-
- Blazer LL, Neubig RR. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: Current progress and future hurdles. Neuropsychopharmacology. 2009;34:126–141. - PubMed
-
- Dev KK. Making protein interactions druggable:Targeting PDZ domains. Nat Rev Drug Discov. 2004;3:1047–1056. - PubMed
-
- Christopherson KS, Hillier BJ, Lim WA, Bredt DS. PSD-95 assembles a ternary complex with the N-methyl-d-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem. 1999;274:27467–27473. - PubMed
-
- Sattler R, et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999;284:1845–1848. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases